TMJ executives liable for $630,000 in penalties
This article was originally published in The Silver Sheet
Executive Summary
Colorado-based TMJ Implants and two executives are liable for civil money penalties of up to $630,000 for not filing 17 adverse event reports, an FDA administrative law judge ruled July 6. The agency claims the dental implant maker did not submit the reports even after being advised of the need to do so in a 2004 warning letter. The company maintains its internal assessment showed the events did not meet the reporting threshold of causing or contributing to a serious injury, and appealed the matter to the FDA commissioner before the agency entered a complaint with the administrative court in July 2005
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.